BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28964630)

  • 1. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis.
    Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM
    HPB (Oxford); 2018 Mar; 20(3):277-284. PubMed ID: 28964630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
    Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
    J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study.
    Sham JG; Ejaz A; Gage MM; Bagante F; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM; He J
    J Gastrointest Surg; 2019 Mar; 23(3):484-491. PubMed ID: 29980977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.
    Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Feb; 117(2):171-181. PubMed ID: 28940257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis.
    Spolverato G; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
    J Surg Oncol; 2017 Sep; 116(3):298-306. PubMed ID: 28513896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment.
    Zhang XF; Beal EW; Chakedis J; Lv Y; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
    J Gastrointest Surg; 2017 Nov; 21(11):1821-1830. PubMed ID: 28730354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
    Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine liver metastasis: The chance to be cured after liver surgery.
    Bagante F; Spolverato G; Merath K; Postlewait LM; Poultsides GA; Mullen MG; Bauer TW; Fields RC; Lamelas J; Marques HP; Aldrighetti L; Tran T; Maithel SK; Pawlik TM
    J Surg Oncol; 2017 May; 115(6):687-695. PubMed ID: 28146608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.
    Morgan RE; Pommier SJ; Pommier RF
    Surgery; 2018 Jan; 163(1):218-225. PubMed ID: 29103583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Liver resection for non-colorectal, non-neuroendocrine hepatic metastases].
    Lang H; Nussbaum KT; Weimann A; Raab R
    Chirurg; 1999 Apr; 70(4):439-46. PubMed ID: 10354843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
    Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
    Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
    Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation.
    Ruzzenente A; Bagante F; Bertuzzo F; Aldrighetti L; Campagnaro T; Ercolani G; Conci S; Giuliante F; Dore A; Ferrero A; Torzilli G; Grazi GL; Ratti F; Cucchetti A; De Rose AM; Russolillo N; Cimino M; Perri P; Guglielmi A; Iacono C
    J Gastrointest Surg; 2019 Jan; 23(1):93-100. PubMed ID: 30242647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis.
    Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss M; Marques HP; Aldrighetti L; Pawlik TM
    J Surg Oncol; 2017 Dec; 116(7):841-847. PubMed ID: 28650564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
    J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
    Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A
    Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma.
    Deutsch GB; Lee JH; Bilchik AJ
    J Am Coll Surg; 2015 Jul; 221(1):26-36. PubMed ID: 26027502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.
    Mayo SC; de Jong MC; Bloomston M; Pulitano C; Clary BM; Reddy SK; Clark Gamblin T; Celinski SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Arrese D; Ferrero A; Schulick RD; Choti MA; Geschwind JF; Strub J; Bauer TW; Adams RB; Aldrighetti L; Mentha G; Capussotti L; Pawlik TM
    Ann Surg Oncol; 2011 Dec; 18(13):3657-65. PubMed ID: 21681380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-stage resection for bilobar colorectal liver metastases: R0 resection is the key.
    Tsim N; Healey AJ; Frampton AE; Habib NA; Bansi DS; Wasan H; Cleator SJ; Stebbing J; Lowdell CP; Jackson JE; Tait P; Jiao LR
    Ann Surg Oncol; 2011 Jul; 18(7):1939-46. PubMed ID: 21298352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.